A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist

https://doi.org/10.1016/j.bmcl.2004.05.023Get rights and content

Abstract

A recently reported dual LPA1/LPA3 receptor antagonist (1) has been modified so as to modulate the basicity, sterics, and dipole moment of the 2-pyridyl moiety. Additionally, the implications of installing nonhydrolyzable phosphate head group isosteres with regard to antagonist potency and selectivity at LPA receptors is described. This study has resulted in the development of the first nonhydrolyzable and presumably phosphatase-resistant LPA3-selective antagonist reported to date.

A recently reported dual LPA1/LPA3 receptor antagonist (1) has been modified so as to modulate the basicity, sterics, and dipole moment of the 2-pyridyl moiety. This study has resulted in the development of the first nonhydrolyzable and presumably phosphatase-resistant LPA3-selective antagonist (13d) reported to date.

  1. Download : Download full-size image

Section snippets

Acknowledgments

Support by NIH (R01-GM52722).

References (24)

  • G Tigyi et al.

    Prog. Lipid Res.

    (2003)
  • V.A Sciorra et al.

    Biochim. Biophys. Acta

    (2002)
  • D.N Brindley et al.

    J. Biol. Chem.

    (1998)
  • S.B Hooks et al.

    FEBS Lett.

    (1998)
  • D.A Dillon et al.

    J. Biol. Chem.

    (1997)
  • J Xu et al.

    J. Biol. Chem.

    (2000)
  • S.B Hooks et al.

    J. Biol. Chem.

    (2001)
  • F Alderton et al.

    J. Biol. Chem.

    (2001)
  • B.H Heasley et al.

    Bioorg. Med. Chem. Lett.

    (2004)
  • A Haudrechy et al.

    Tetrahedron

    (2000)
  • J Nieschalk et al.

    Tetrahedron

    (1996)
  • W.L Santos et al.

    Bioorg. Med. Chem. Lett.

    (2004)
  • Cited by (33)

    • The development of modulators for lysophosphatidic acid receptors: A comprehensive review

      2021, Bioorganic Chemistry
      Citation Excerpt :

      Among them, a compound with a methoxy dimethylpyridine substituent (38) (Fig. 11) was found to be a highly subtype-selective LPA3 antagonist (IC50 = 150 nM) without any activity on the LPA1 receptor (Table 1). Another compound with a trifluoroethoxy substituent, VPC51098 (Fig. 11), was found to be a potent LPA1/LPA3 dual antagonist (LPA1 IC50 = 84 nM, LPA3 IC50 = 48 nM) with greater potency at the LPA3 receptor than VPC12249 [92]. Based on the structure of VPC51098, the labile phosphate head group was converted to vinyl phosphonate to achieve better stability.

    • Reprint of: "synthetic lipids and their role in defining macromolecular assemblies"

      2016, Chemistry and Physics of Lipids
      Citation Excerpt :

      These bioactive lipids and their receptor targets seem particularly relevant in neuropathic pain (Aikawa et al., 2015; Ueda et al., 2013; Tsuda et al., 2011), inflammation (Knowlden and Georas, 2014; Mazereeuw et al., 2013; Sevastou et al., 2013; Zhao and Natarajan, 2013), and cancer (Bekele and Brindley, 2012; Leblanc and Peyruchaud, 2015; Tsujiuchi et al., 2014). Our understanding of the molecular interactions of these bioactive lipids with their molecular targets has been significantly impacted by the availability of both natural and synthetic chemical probes with which to define stereospecificity (Yokoyama et al., 2002; Zhang et al., 2004; Heise et al., 2001), regiospecificity (Fujiwara et al., 2005), and structure activity relationships(SAR) (Heise et al., 2001; Lynch et al., 1997; Hooks et al., 1998; Hopper et al., 1999; Santos et al., 2004; Heasley et al., 2004a,b; Qian et al., 2003a,b; Xu et al., 2003, 2004a,b, 2005; Gajewiak et al., 2007; Zhang et al., 2009; Jiang et al., 2013). Studies of the stereospecificity of LPA targets utilized AGP analogs (Yokoyama et al., 2002; Zhang et al., 2004; Simon et al., 1982) or more distant relatives of LPA (Heise et al., 2001; Qian et al., 2003b; Xu et al., 2009) due to the acknowledged positional instability of the acyl group in lysophospholipids (Pluckthun and Dennis, 1982; Croset et al., 2000; Kodali et al., 1990).

    • Synthetic lipids and their role in defining macromolecular assemblies

      2015, Chemistry and Physics of Lipids
      Citation Excerpt :

      These bioactive lipids and their receptor targets seem particularly relevant in neuropathic pain (Aikawa et al., 2015; Ueda et al., 2013; Tsuda et al., 2011), inflammation (Knowlden and Georas, 2014; Mazereeuw et al., 2013; Sevastou et al., 2013; Zhao and Natarajan, 2013), and cancer (Bekele and Brindley, 2012; Leblanc and Peyruchaud, 2015; Tsujiuchi et al., 2014). Our understanding of the molecular interactions of these bioactive lipids with their molecular targets has been significantly impacted by the availability of both natural and synthetic chemical probes with which to define stereospecificity (Yokoyama et al., 2002; Zhang et al., 2004; Heise et al., 2001), regiospecificity (Fujiwara et al., 2005), and structure activity relationships(SAR) (Heise et al., 2001; Lynch et al., 1997; Hooks et al., 1998; Hopper et al., 1999; Santos et al., 2004; Heasley et al., 2004a,b; Qian et al., 2003a,b; Xu et al., 2003, 2004a,b, 2005; Gajewiak et al., 2007; Zhang et al., 2009; Jiang et al., 2013). Studies of the stereospecificity of LPA targets utilized AGP analogs (Yokoyama et al., 2002; Zhang et al., 2004; Simon et al., 1982) or more distant relatives of LPA (Heise et al., 2001; Qian et al., 2003b; Xu et al., 2009) due to the acknowledged positional instability of the acyl group in lysophospholipids (Pluckthun and Dennis, 1982; Croset et al., 2000; Kodali et al., 1990).

    View all citing articles on Scopus
    View full text